key: cord-0317114-kf0zoh43
authors: Tarrés-Freixas, Ferran; Trinité, Benjamin; Pons-Grífols, Anna; Romero-Durana, Miguel; Riveira-Muñoz, Eva; Ávila-Nieto, Carlos; Pérez, Mónica; Garcia-Vidal, Edurne; Pérez-Zsolt, Daniel; Muñoz-Basagoiti, Jordana; Raïch-Regué, Dàlia; Izquierdo-Useros, Nuria; Blanco, Ignacio; Noguera-Julián, Marc; Guallar, Victor; Lepore, Rosalba; Valencia, Alfonso; Vergara-Alert, Júlia; Clotet, Bonaventura; Ballana, Ester; Carrillo, Jorge; Segalés, Joaquim; Blanco, Julià
title: SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant
date: 2021-08-03
journal: bioRxiv
DOI: 10.1101/2021.08.03.454861
sha: fabfc5af95532fb2a3e1a6a3f11275796daaa232
doc_id: 317114
cord_uid: kf0zoh43

SARS-CoV-2 variants display enhanced transmissibility and/or immune evasion and can be generated in humans or animals, like minks, thus generating new reservoirs. The continuous surveillance of animal susceptibility to new variants is necessary to predict pandemic evolution. In this study we demonstrate that, compared to the B.1 SARS-CoV-2 variant, K18-hACE2 transgenic mice challenged with the B.1.351 variant displayed a faster progression of infection. Furthermore, we also report that B.1.351 can establish infection in wildtype mice, while B.1 cannot. B.1.351-challenged wildtype mice showed a milder infection than transgenic mice, confirmed by detectable viral loads in oropharyngeal swabs and tissues, lung pathology, immunohistochemistry and serology. In silico models supported these findings by demonstrating that the Spike mutations in B.1.351 resulted in increased affinity for both human and murine ACE2 receptors. Overall, this study highlights the plasticity of SARS-CoV-2 animal susceptibility landscape, which may contribute to viral persistence and expansion.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a virus of zoonotic origin responsible for the Coronavirus Disease 2019 (COVID-19) that emerged by the end of 2019 in Wuhan, China (Holmes et al., 2021) . From there, it rapidly spread across the world fuelling an unprecedented pandemic. The year 2020 ended with a growing awareness on SARS-CoV-2 variants that could potentially be more infectious and/or could evade immune responses elicited by previous infection with predecessor variants and/or vaccination (Trinité et al., 2021; Wang et al., 2021a) .

To date, mass genotyping has prompted the identification of several variants of concern (VOC) (Mullen et al., 2020; Wang et al., 2021b) : B.1.1.7/alpha -first described in the UK-showed higher transmissibility; B.1.351/beta, initially described in South Africa and P.1/gamma, isolated in Brazil, both demonstrated increased resistance to neutralizing antibodies elicited by other variants and/or vaccination (Dejnirattisai et al., 2021; Planas et al., 2021) . More recently, the B.1.617.2/delta variant was identified in India and seems en route to rapidly supplant all other described SARS-CoV-2 variants (Parums, 2021) . B.1.351's greater resistance to neutralisation is especially concerning since it could considerably impact on vaccination programs (Shen et al., 2021) . Furthermore, B.1.617.2 variant shows a combination of both higher transmissibility and resistance to neutralization . Mutations in the spike (S) protein are responsible for these phenotypes by modifying neutralising epitopes and/or increasing the affinity for the human angiotensin converting enzyme 2 (hACE2) receptor (Gan et al., 2021) . In addition to enhance the transmissibility between humans, these mutations can also alter the susceptibility of other host species of the virus, therefore broadening the animal reservoir (Conceicao et al., 2020; Liu et al., 2021; Piplani et al., 2021) .

Also, animals are well-known coronavirus reservoirs (Menachery et al., 2017) . While the intermediate host species of SARS-CoV-2 remains elusive, transmission from humans to domestic, farm and zoo animals has been documented (Muñoz-Fontela et al., 2020; Oreshkova et al., 2020; Segalés et al., 2020) . The landscape of susceptibility species is also governed by S protein mutations, which can modulate the affinity to animal ACE2 (Garry, 2021) . Notably, it has already been reported that new variants such as B.1.351 can infect SARS-CoV-2 resistant species like mice (Montagutelli et al., 2021) . However, a complete in vivo susceptibility analysis has not yet been carried out.

The resistance of wildtype (WT) mice to SARS-CoV-2 infection made transgenic hACE2 mice one of the main experimental models for the in vivo study of novel vaccines and treatments (Bao et al., 2020; Jiang et al., 2020) . The K18-hACE2 strain, a model used for SARS-CoV studies, is susceptible to SARS-CoV-2 infection and develops a severe disease. In these mice the hACE2 transgene is driven by the cytokeratin-18 (K18) gene promoter and hence it is expressed in many tissues, like lungs, intestines, and brain (Zheng et al., 2021) . Widespread hACE2 expression drives a rapid progression of the disease, including massive brain infection, that does not recapitulate COVID-19 progression in humans (Winkler et al., 2020) . Some groups, pursuing more physiological models, have attempted to mutate SARS-CoV-2 S protein to increase its tropism for mice Sun et al., 2020) . Alternatively, WT mice susceptibility to new SARS-CoV-2 variants, like B.1.351, may turn into an opportunity to develop a mouse model that better mimics the disease course, but may also represent a new viral reservoir.

The objective of this work was to compare the infectivity of B.1 and B.1.351 SARS-CoV-2 variants in both hACE2 transgenic and WT mice and characterise the progression of infection and pathological outcome. We provide evidence that B.1.351 displays a faster disease progression in hACE2 transgenic mice, while expanding tropism to WT mice. These results were consistent with molecular modelling suggesting an increased affinity of the B.1.351 associated S protein to both human and murine ACE2 and may have implications for experimental models of infection and, importantly, to SARS-CoV-2 ecology.

The biologic biosafety committee of Germans Trias i Pujol Research Institute (IGTP) approved the execution of SARS-CoV-2 experiments at the BSL3 laboratory of the Centre for Bioimaging and Comparative Medicine (CMCiB, Badalona, Spain). The SARS-CoV-2 variants used in this study were isolated from nasopharyngeal swabs of hospitalised patients in Spain as described elsewhere . Briefly, viruses were propagated in VeroE6 cells (CRL-1586; ATCC, Virginia, VA, USA) for two passages and recovered by supernatant collection. The sequences of the two SARS-CoV-2 variants tested here were deposited at the GISAID Repository (http://gisaid.org) with accession IDs EPI_ISL_510689 and EPI_ISL_1663571, respectively. EPI_ISL_510689 was the first SARS-CoV-2 virus isolated in Catalonia on March 2020 and, compared to the Wuhan/Hu-1/2019 strain, this isolate had the Spike mutations D614G, R682L, which are associated to the B.1 lineage. EPI_ISL_1663571 was isolated in February 2021 and showed the mutations associated with the B.1.351 or beta variant, and hence it will be referred as B.1.351. Viral stocks were titrated to use equivalent TCID 50 /mL on Vero E6 cells as described previously .

All animal procedures were performed under the approval of the Committee on the Ethics of Animal Experimentation of the IGTP and the authorisation of Generalitat de Catalunya (code: 11222).

B6.Cg-Tg(K18-ACE2)2Prlmn/J (or K18-hACE2) hemizygous transgenic mice (034860; Jackson Immunoresearch, West Grove, PA, USA) were bred at CMCiB by pairing hemizygous males for Tg(K18-ACE2)2Prlmn (or K18-hACE2) with non-carrier B6.Cg females. The genotype of the offspring regarding Tg(K18-ACE2)2Prlmn was determined by qPCR at the IGTP's Genomics Platform. Animals were kept in the BSL-3 facility during the whole experiment.

A total of 25 adult mice were used in this experiment (17 K18-hACE2 hemizygous mice and 8 non-transgenic WT mice from the same breed). All groups (4 to 7 animals) were sex balanced. Mice were anaesthetised with isoflurane (FDG9623; Baxter, Deerfield, IL, USA) and challenged with either B.1 or B.1.351 SARS-CoV-2 isolates, or PBS (uninfected control group). Infection was performed using 1000 TCID 50 in 50 μL of PBS (25 μl/nostril). Mice fully recovered from the challenge and anaesthesia procedures.

After SARS-CoV-2 challenge, body weight and clinical signs were monitored daily.

Two to three animals per group were euthanised 3 days post-infection (dpi) for viral load quantification. The rest of the animals were euthanised 7 dpi according to the experimental design (Supplementary Figure 1a) , or earlier if they reached humane endpoint (body weight loss superior to 20% of the initial body weight and/or the display of moderate to severe neurological signs resulting from brain infection). Euthanasia was performed under deep isoflurane anaesthesia by whole blood extraction via cardiac puncture and was confirmed by cervical dislocation. Serum was recovered from whole blood following 10 min centrifugation at 4,000 x g. Lung, brain and nasal turbinate were collected for viral load determination and immunohistochemistry analysis.

The humoral response against SARS-CoV-2 was evaluated using an in-house ELISA, as previously reported . All samples were tested in the same plate in antigen coated and antigen-free wells for background subtraction. Briefly, half Nunc Maxisorp ELISA plates were coated with 50 μ L of Spike, RBD or nucleocapsid protein (NP, SinoBiologicals, Beijing, China), all at 1 μ g/mL in PBS and incubated overnight at 4ºC. Then, plates were washed and blocked using PBS/1% of bovine serum albumin (BSA, Miltenyi biotech) for two hours at room temperature. After that, duplicates of each sample were added in the same plate to the wells coated with and without antigen.

Samples were assayed at 1/200 (IgG determination) or 1/50 (IgM determination) dilution in blocking buffer overnight at 4ºC. The next day, after washing, plates were incubated for 1 hour at room temperature with HRP conjugated-(Fab)2 Goat antimouse IgG (Fc specific) or Goat anti-mouse IgM (both 1/10000, Jackson Immunoresearch). Then, plates were washed and revealed with o-Phenylenediamine dihydrochloride (OPD, Sigma Aldrich) and stopped using 2N of H 2 SO 4 (Sigma Aldrich). The signal was analyzed as the optical density (OD) at 492 nm with noise correction at 620 nm. The specific signal for each antigen was calculated as corrected optical density after subtracting the background signal obtained for each sample in antigen-free wells.

Viral load was determined in several tissues (lung, brain, oropharyngeal swab and nasal turbinate). Briefly, a piece of each tissue (100 mg approximately) was collected in 1.5 mL Sarstedt tubes (72,607; Sarstedt, Nümbrecth, Germany) containing 500 µL of DMEM medium (11995065; ThermoFisher Scientific) supplemented with 1% penicillin-streptomycin (10378016; ThermoFisher Scientific, Waltham, MA, USA). A 1.5 mm Tungsten bead (69997; QIAGEN, Hilden, Germany) was added to each tube and samples were homogenised twice at 25 Hz for 30 sec using a TissueLyser II (85300; QIAGEN) and centrifuged for 2 min at 2,000 x g. Supernatants were stored at -80 °C until use. RNA extraction was performed by using Viral RNA/Pathogen Nucleic Acid Isolation kit (A42352, ThermoFisher Scientific), optimized for a KingFisher instrument (5400610; ThermoFisher Scientific), following manufacturer's instructions. load of each sample was determined in triplicate and mean viral load (in copies/mL) was extrapolated from the standard curve and corrected by the corresponding dilution factor. Mouse gapdh gene expression was measured in duplicate for each sample using TaqMan® gene expression assay (Mm99999915_g1; ThermoFisher Scientific) as amplification control. The 2 -ΔCT value was calculated for each sample.

Formalin-fixed lung, nasal turbinate and brain samples were routinely processed for histopathology, and haematoxylin&eosin-stained slides were examined under optical microscope. A semi-quantitative approach based on the amount of inflammation (none, mild, moderate, or severe) was used to establish the damage caused by SARS-CoV-2 infection in mice, following a previous published scoring system (Vidal et al., submitted ).

An immunohistochemistry (IHC) technique to detect SARS-CoV-2 nucleoprotein (NP) antigen using the rabbit monoclonal antibody (40143-R019, Sino Biological, Beijing, China) at a 1:15,000 dilution, was applied on nasal turbinate, lung and brain sections from all animals. The amount of viral antigen in tissues was semi-quantitatively scored (low, moderate and high amount, or lack of antigen detection) (Vidal et al., submitted) .

Since no experimental structure of murine ACE2 (mACE2) in complex with the spike protein of SARS-CoV-2 was available, we ran MODELLER v10.1 (Šali and Blundell, 1993 ) to generate homology models. As a template, the crystallographic structure of hACE2 in complex with the spike RBD of the initial virus variant (PDB id 6M0J) was used. We created a total number of 10 models (identified as mACE2-WT RBD). In a second step, using the MODELLER models as input, we ran FoldX v5 (Schymkowitz et al., 2005; Delgado et al., 2019) to model the mutations associated with the B.1.351 variant of the virus, obtaining 10 additional models (named mACE2-B.1.351 RBD) ( Supplementary Fig. 3 ). All FoldX parameters had default values except parameter vdwDesign that we set to zero. We evaluated each model with FoldX and pyDock (Cheng et al., 2007) which have achieved good performance predicting the impact of mutations in protein-protein complexes (Amengual-Rigo et al., 2021) . As a control, we repeated the procedure described above to generate models of hACE2 -in complex with the RBD of the WT virus (hACE2 -WT RBD) and the B.1.351 variant (hACE2 -B.1.351 RBD). As before, we ended up with 10 different models per complex type. We visualized and produced the pictures of the models with UCSF Chimera (Pettersen et al., 2004) . 

In parallel to the challenge experiment described above, K18-hACE2 negative mice from the same breed WT were also challenged with the B .1 (n=4) Two relevant aspects of B.1.351 SARS-CoV-2 infection in WT mice were that virus could not be detected in the brain (Figure 1d) , and that viral loads from the swab, lung and nasal turbinate of animals euthanised 3 dpi were higher than viral loads in the samples recovered at endpoint (Figure 1b,c,e) . This could explain why, despite getting infected, WT animals did not display severe signs as hACE2-expressing mice did.

Reduction of viral loads in WT mouse tissues may reflect a rapid and effective viral clearance by the immune response (Figure 1f,g 

To estimate the effect of the mutations associated with the B.1.351 variant on the binding affinity to ACE2, the protein-protein interaction models were evaluated with two levels of theory: FoldX and pyDock. Both models yielded significantly lower energies (i.e., higher binding affinity predictions) for the B.1.351 variant spike RBD in complex with both human and murine ACE2 (Wilcoxon paired test p=0.01) (Figure 3) .

These results suggest that the effect of B.1.351 mutations could improve binding to human and murine ACE2.

A detailed analysis of the modelled structures provided a mechanistic description of the mutation effects at the molecular level. The exploration of the models suggested that the mutations did not produce significant structural changes (Supplementary Figure 4) .

Mutation K417N caused the loss of a salt bridge between Lys417 and hACE2 Asp30, reducing the affinity to the human receptor. Interestingly, in mice, no salt bridge is formed between Lys417 and mACE2 Asn30, and hence binding affinity is not negatively affected by the mutation (Supplementary Figure 4a-d) . A similar case occurs with mutation E484K, which induces the loss of a salt bridge between Glu484 and Lys31 in hACE2, but not in mACE2, where this salt bridge cannot be formed between This effect would be reduced by the loss of salt bridges caused by mutations K417N and E484K in human, but not in mice.

Altogether, molecular analyses suggest that multiple mutations within the B.1.351 SARS-CoV-2 Spike enhanced the affinity for mACE2, which might explain why WT mice could get infected by this variant.

This study shows that the SARS-CoV-2 B.1.351 variant can establish infection in WT mice, in line with previous findings (Montagutelli et al., 2021) . Compared to hACE2expressing transgenic mice that developed a severe clinical course and pathology upon SARS-CoV-2 infection, WT mice displayed a milder phenotype. This milder outcome could be comparable to SARS-CoV-2 infection in other animal models, in which lung replication and viral pneumonia is detected, but eventually resolved by the action of the immune response , and could open the door to develop better SARS-CoV-2 models than transgenic hACE2 mice. This, however, also raises concerns on how new variants with increased affinity to ACE2 could expand their host tropism to animal species that were non-susceptible to earlier SARS-CoV-2 variants, potentially generating new zoonotic reservoirs and increasing the risk of new spillover and spread of new variants in humans.

Further studies will prove whether, in a natural setting, increased affinity to mACE2 by B.1.351 mutations can result in an effective SARS-CoV-2 infection, or whether the mild symptoms and viral control in WT mice caused by B.1.351 were just due to the virus' inability to sustain infection. Still, this study confirms the need to monitor SARS-CoV-2 VOC beyond its interaction with humans (transmissibility, pathogenicity and immune evasion) and from a "One Health" perspective. Tyr501 can have a cation-pi interaction with hACE2 Lys353 in human (k), and a pi-pi interaction with mACE2 His353 in mice (l). The analysis suggests that the increase in affinity due to mutation N501Y is partially reduced by the loss of salt bridges in human, but not in mice.

UEP: an open-source and fast classifier for predicting the impact of mutations in protein-protein complexes

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Protection against reinfection with D614-or G614-SARS-CoV-2 isolates in golden Syrian hamster

pyDock: Electrostatics and desolvation for effective scoring of rigid-body protein-protein docking

The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins

Antibody evasion by the P.1 strain of SARS-CoV-2

FoldX 5.0: working with RNA, small molecules and a new graphical interface

Structural Modeling of the SARS-CoV-2 Spike/Human ACE2 Complex Interface can Identify High-Affinity Variants Associated with Increased

Mutations arising in SARS-CoV-2 spike on sustained human-tohuman transmission and human-to-animal passage

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

The Origins of SARS-CoV-2: A Critical Review

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Viral infection and transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant. medRxiv

Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2

Jumping species-a mechanism for coronavirus persistence and survival

The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice

Animal models for COVID-19

SARS-CoV-2

Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2

Siglec-1 on dendritic cells mediates SARS-CoV-2 <em>trans</em>-infection of target cells while on macrophages triggers proinflammatory responses

UCSF Chimera--a visualization system for exploratory research and analysis

In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen

Comparative Protein Modelling by Satisfaction of Spatial Restraints

The FoldX web server: an online force field

Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

Characterization and structural basis of a lethal mouse-adapted SARS-CoV-2. bioRxiv

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses 13

Chronological brain lesions after SARS-CoV-2 infection in hACE2 transgenic mice

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice

The authors would like to acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility and Y. Rosales and R. Ampudia from the CMCiB for their unvaluable help with the K18-hACE2 colony. We also thank M. Parera from IrsiCaixa for her outstanding help in sequencing viral variants.